

ALIMERA SCIENCES INC  
Form 8-K  
September 30, 2014

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): September 30, 2014  
ALIMERA SCIENCES, INC.  
(Exact name of registrant as specified in its charter)

Delaware	001-34703	20-0028718
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

6120 Windward Parkway  
Suite 290  
Alpharetta, Georgia  
(Address of Principal Executive Offices)  
Registrant's telephone number, including area code: (678) 990-5740

30005  
(Zip Code)

Not Applicable

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

Item 8.01. Other Events.

On September 30, 2014, Alimera Sciences, Inc. (“Alimera”) issued a press release announcing that it has received the second and final advance under the Loan and Security Agreement that Alimera’s subsidiary in the United Kingdom, Alimera Sciences Limited, entered into with Hercules Technology Growth Capital, Inc. in April of this year. Receipt of the \$25 million was conditional on the approval, on or before October 31, 2014, of ILUVIEN® by the U.S. Food and Drug Administration (FDA). On September 26, 2014, the FDA approved ILUVIEN® for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). Alimera will use the advance to fund a \$25 million milestone payment owed to the licensor of certain intellectual property as a result of the recent FDA approval of ILUVIEN®. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein.

---

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release of Alimera Sciences, Inc. dated September 30, 2014

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALIMERA SCIENCES, INC.

Dated: September 30, 2014

By: /s/ RICHARD S. EISWIRTH, JR.

Name: Richard S. Eiswirth, Jr.

Title: Chief Operating Officer and  
Chief Financial Officer